MGNX -- MacroGenics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGNX -- MacroGenics

MGNX 1.590

-6.2%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/26/2019 12:31:57 AM
	Read Replies (1) of 188

Many street oncology experts were quick to point that luck of absolute numbers in Sofia trials data release suggest POOR outcome, especially future main end-point, OS! What is ~1.5m additional benefit in mPFS? NOTHING! ALL will agree with that! By the same measure, the same field expert were GLORIFYING CK-426 results where mPFS was at HR~0.60 or better. Actually, by next tweet slide, twitter.com Keytruda has (projected, maybe less, maybe more???)~3 months added benefit (in mPFS) to Axitinib mPFS of 12.2 months (25% additional benefit), and that results are , God forbid, so good that one can take it as dietary supplement (GRAS by single world). Thanks GOD I am so naive, and can not comprehend such sophisticated reasoning.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next